EUVIMEDEUVIMED entdecken
Open Access

Predictive Value of C-Peptide Measures for Clinical Outcomes of β-Cell Replacement Therapy in Type 1 Diabetes: Report From the Collaborative Islet Transplant Registry (CITR)

David A Baidal iD, Cassandra M Ballou, Michael R Rickels iD, Thierry Berney, Francois Pattou, Elizabeth H Payne, Franca B Barton, Rodolfo Alejandro iD, CITR Investigators

Diabetes Care · 01.04.2023 · 46 (4) · 697-703

DOI: 10.2337/dc22-1155 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Care, online erschienen am 17.01.2023. Verfasst von David A Baidal und 8 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Research Institute, Miller School of Medicine, University of Miami, Miami, FL. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Islets of Langerhans Transplantation. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, JDRF, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE To determine C-peptide measures and levels associated with positive glycemic control outcomes following islet transplant (ITx) in type 1 diabetes. RESEARCH DESIGN AND METHODS We evaluated Collaborative Islet Transplant Registry (CITR) islet-alone recipients with pretransplant C-peptide <0.1 nmol/L and mean follow-up of 4.6 ± 1.1 years (n = 677). Receiver operating characteristic area under the curve (ROC-AUC) was used to evaluate the predictive value of fasting and stimulated glucose and C-peptide measures for seven primary outcomes: 1) absence of severe hypoglycemic events (ASHEs); 2) HbA1c <7.0%; 3) HbA1c <7.0% and ASHEs; 4) HbA1c ≤6.5%; 5) HbA1c ≤6.5% and ASHEs; 6) insulin independence; and 7) ASHEs, HbA1c ≤6.5%, and insulin independence (the optimal outcome). Measures with the highest ROC-AUC were selected for determination of optimal cut points. RESULTS Fasting C-peptide was highly predictive for ASHE (ROC-AUC 0.906; optimal cut point 0.070 nmol/L) and the optimal outcome (ROC-AUC 0.845; optimal cut point 0.33 nmol/L). Mixed-meal tolerance test (MMTT)–stimulated C-peptide-to-glucose ratio (CPGR) outperformed both fasting and stimulated C-peptide for all outcomes except ASHE. The optimal cut point for the optimal outcome was 0.12 nmol/mmol for MMTT-stimulated CPGR and 0.97 nmol/L for MMTT-stimulated C-peptide. CONCLUSIONS Fasting C-peptide reliably predicts ITx primary outcomes. MMTT-stimulated CPGR provides marginally better prediction for composite ITx outcomes, including insulin independence. In the absence of an MMTT, a fasting C-peptide ≥0.33 nmol/L is a reassuring measure of optimal islet graft function. C-peptide targets represent excellent and easily determinable means to predict glycemic control outcomes after ITx and should be considered as potential goals of β-cell replacement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Islets of Langerhans TransplantationHumansC-PeptideBlood GlucoseGlycated HemoglobinInsulinGlucoseHypoglycemic AgentsInsulin, Regular, Human

Substanzen

C-PeptideBlood GlucoseGlycated HemoglobinInsulinGlucoseHypoglycemic AgentsInsulin, Regular, Human

Autor:innen und Institutionen

  • Diabetes Research Institute, Miller School of Medicine, University of Miami, Miami, FL.
  • Collaborative Islet Transplant Registry Coordinating Center, The EMMES Company, LLC, Rockville, MD.
  • Institute for Diabetes, Obesity and Metabolism, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
  • Division of Transplantation, Department of Surgery, Geneva University Hospitals, Geneva, Switzerland.
  • Department of General and Endocrine Surgery, Centre Hospitalier Universitaire de Lille, Translational Research for Diabetes, INSERM, Université de Lille, Lille, France.

ORCID-Profile: David A Baidal, Michael R Rickels, Rodolfo Alejandro

Förderung

  • NIDDK NIH HHS
  • JDRF
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Baidal, D. A., Ballou, C. M., Rickels, M. R., Berney, T., Pattou, F., Payne, E. H., Barton, F. B., Alejandro, R., & CITR Investigators (2023). Predictive Value of C-Peptide Measures for Clinical Outcomes of β-Cell Replacement Therapy in Type 1 Diabetes: Report From the Collaborative Islet Transplant Registry (CITR). Diabetes Care, 46(4), 697-703. https://doi.org/10.2337/dc22-1155

Vancouver

Baidal DA, Ballou CM, Rickels MR, Berney T, Pattou F, Payne EH, et al. Predictive Value of C-Peptide Measures for Clinical Outcomes of β-Cell Replacement Therapy in Type 1 Diabetes: Report From the Collaborative Islet Transplant Registry (CITR). Diabetes Care. 2023;46(4):697-703. doi:10.2337/dc22-1155

BibTeX
@article{Baidal2023,
  author = {Baidal, David A and Ballou, Cassandra M and Rickels, Michael R and Berney, Thierry and Pattou, Francois and Payne, Elizabeth H and Barton, Franca B and Alejandro, Rodolfo and CITR Investigators, CITR Investigators},
  title = {Predictive Value of C-Peptide Measures for Clinical Outcomes of β-Cell Replacement Therapy in Type 1 Diabetes: Report From the Collaborative Islet Transplant Registry (CITR)},
  journal = {Diabetes Care},
  year = {2023},
  volume = {46},
  number = {4},
  pages = {697--703},
  doi = {10.2337/dc22-1155}
}
Kostenlos starten →